Long‐Term Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion in Moderate‐to‐Severe Plaque Psoriasis: Phase 3 Open‐Label Study
Long‐Term Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion in Moderate‐to‐Severe Plaque Psoriasis: Phase 3 Open‐Label Study
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now